Inter Parfums (IPAR)
(Delayed Data from NSDQ)
$131.15 USD
+1.67 (1.29%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $130.98 -0.17 (-0.13%) 8:52 AM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$131.15 USD
+1.67 (1.29%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $130.98 -0.17 (-0.13%) 8:52 AM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
International Flavors (IFF) Q4 Earnings Lag Estimates, Dip Y/Y
by Zacks Equity Research
International Flavors' (IFF) Q4 top line reflects softness in the Pharma and Nourish segments, offset by growth in the Scent, and Health & Biosciences segments.
Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y
by Zacks Equity Research
Medifast's (MED) Q4 results reflect the impacts of poor customer acquisition. However, it is showing resilience, banking on its strategic focus on medically supported weight loss, indicating potential for growth.
Things to Note Ahead of Inter Parfums' (IPAR) Q4 Earnings
by Zacks Equity Research
Inter Parfums' (IPAR) fourth-quarter 2023 performance will likely reflect the adverse impact of rising advertising and promotion costs. Nevertheless, a solid brand portfolio is likely to aid growth.
4 Cosmetics Stocks Worth Watching on Robust Industry Trends
by Ansuiya Mohta
The Zacks Cosmetics industry companies are benefiting from a burgeoning demand for skincare and personal care products. Focus on innovations is propelling The Estee Lauder Companies (EL), COTY, Inter Parfums (IPAR) and Helen of Troy (HELE).
Pilgrim's Pride (PPC) Q4 Earnings Coming Up: Factors to Note
by Zacks Equity Research
Pilgrim's Pride (PPC) witnesses strength in its Mexico and Europe operations. A focus on key customers and supply-chain improvements work well for the company.
Can Cheniere (LNG) Pull Off a Strong Show in Q4 Earnings?
by Zacks Equity Research
Robust export volumes and lower costs are likely to have boosted Cheniere Energy's (LNG) profit levels in the fourth quarter.
Itron (ITRI) to Post Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Itron's (ITRI) fourth-quarter performance is likely to have benefited from continued momentum across all business segments.
Factors to Note Ahead of Coterra Energy's (CTRA) Q4 Earnings
by Zacks Equity Research
Coterra Energy (CTRA) beat the Zacks Consensus Estimate for earnings in each of the last four quarters, resulting in an earnings surprise of 111.8%, on average.
Inter Parfums (IPAR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inter Parfums (IPAR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Suncor's (SU) Q4 Earnings Preview: Key Things to Consider
by Zacks Equity Research
Suncor Energy (SU) beat the Zacks Consensus Estimate for earnings in each of the last four quarters.
Wolverine (WWW) Q4 Earnings Coming Up: Factors Worth Knowing
by Zacks Equity Research
Wolverine (WWW) battles challenges in the outdoor category, soft demand in the U.S. and European wholesale businesses and weakness in the DTC channel.
Here's How FEMSA (FMX) is Placed Just Ahead of Q4 Earnings
by Zacks Equity Research
FEMSA's (FMX) Q4 results are expected to reflect effective growth strategies and robust market demand, which are likely to drive growth across all units.
Helen of Troy (HELE) Benefits From Brand Strength & Project Pegasus
by Zacks Equity Research
Helen of Troy (HELE) is on track with Project Pegasus, which aims to expand operating margins via improved efficiency and lower costs.
What's in the Cards for Keurig Dr Pepper (KDP) in Q4 Earnings?
by Zacks Equity Research
Keurig Dr Pepper's (KDP) fourth-quarter 2023 results are likely to reflect gains from brand strength, significant pricing actions and a solid performance in its cold beverages.
Marathon (MRO) Q4 Earnings on Deck: Here's How It Will Fare
by Zacks Equity Research
Lower commodity price realizations and the increase in costs are likely to have impacted the fourth-quarter earnings of Marathon Oil (MRO).
TreeHouse Foods (THS) Q4 Earnings Beat, Sales Decline Y/Y
by Zacks Equity Research
TreeHouse Foods' (THS) fourth-quarter fiscal 2023 results reflect soft sales and earnings due to supply-chain hurdles at one of the broth facilities.
International Flavors (IFF) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
International Flavors' (IFF) Q4 results are likely to reflect the impacts of lower volumes and escalating costs.
Service Corp (SCI) Hikes Dividend: What Else Should You Know?
by Zacks Equity Research
Service Corp (SCI) announces a dividend increase, showcasing its commitment to delivering value to its shareholders.
Medifast (MED) Q4 Earnings Coming Up: What Should You Know?
by Zacks Equity Research
Medifast's (MED) fourth-quarter results are likely to reflect the impacts of macroeconomic challenges like inflation, while key growth initiatives like innovation bode well.
Is Inter Parfums (IPAR) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Here is how Inter Parfums (IPAR) and Kerry Group PLC (KRYAY) have performed compared to their sector so far this year.
Dutch Bros (BROS) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Dutch Bros' (BROS) fourth-quarter 2023 top-line results are likely to reflect gains from strength in its underlying business and expansion initiatives.
Nu Skin (NUS) Q4 Earnings Top Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2023 results reflect the persistence of macroeconomic challenges and hurdles related to business transformation, offset by growth in some regions.
Nu Skin Enterprises (NUS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 27.59% and 1.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Molson Coors (TAP) Q4 Earnings & Sales Beat on Brand Strength
by Zacks Equity Research
Molson Coors' (TAP) fourth-quarter 2023 results benefit from brand strength and impressive performances across both its business units.
General Mills' (GIS) HMM Strategy Aids Despite Troubled Pet Unit
by Zacks Equity Research
General Mills' (GIS) HMM strategy and innovations position it for growth despite challenges, particularly in the Pet segment.